Skip to main content
Berlin-based FinTech start-up Nufin GmbH, which operates under the name Moss, has raised around 25 million Euros in a Series A-2 financing round including investments from Valar Ventures and other existing shareholders such as Cherry Ventures and Global Founders Capital. A team from the international law firm Taylor Wessing, led by Hamburg-based partner Jens Wolf, advised Nufin on all legal issues in connection with the Series A-2 financing round. Moss, in partnership with Raisin Bank, offers physical and virtual credit cards as well as expense management software to small and medium-sized…
With Israeli startups continuing to break records in fundraising, the co-heads of our international Israel group, Josef Fuss and Nathan Krapivensky, outline potential opportunities in Europe and how they envisage the next phase of success for these businesses. London is ready and waiting for Israeli entrepreneurs and technology companies. While Israeli entrepreneurs and startups have traditionally been focused on expanding to the US - and for good reason since America has given such startups access to capital, opportunities for expansion in one of the biggest markets, and seemingly endless…
LexisNexis is profiling our partner and international co-head of Life Sciences and Healthcare Alison Dennis as part of its Meet the Experts section.
LINK Medical is pleased to announce that Maria Hortlund joins the Market Access team as a RWE Manager. Maria has over 15 years’ experience within RWE in the Nordics. She holds a PhD in Epidemiology and brings extensive knowledge of RWE-studies, from study concept to final report. She joins LINK Medical from the Karolinska Institute where she has had experience with national health registries, hospital data and biobanks in the Nordics and published 25 peer reviewed papers on cervical cancer screening. RWE is the evidence obtained from real-world observational data generated during routine…
AMSBIO is a knowledgeable supplier of products dedicated to exosome research that includes high quality reagents and kits that are quick, affordable and easy to use.The latest addition to this portfolio is a new range of tools for isolating and purifying overall or specific exosome sub-populations from small volumes of sample in an efficient, faster and cheaper way. For applications that require total exosome isolation from biological fluids including plasma, serum and urine as well as cell culture media, AMSBIO has launched ExoPure™ Reagent - a fast and convenient one-step method…
Click here to view the August edition of Dates for Your Diary.
Click here to view the August 2021 edition of eNews
Hamburg-based Exit Games GmbH has entered into a strategic partnership with Skillz Inc.. As part of the strategic partnership, Skillz has acquired a minority interest in Exit Games in the amount of 50 million US dollars. A team of the international law firm Taylor Wessing, led by Hamburg-based partner Jens Wolf, advised Exit Games on all legal issues in connection with the transaction. Exit Games is the developer of the well-known network and multiplayer engine Photon, which allows software developers to create and host synchronous real-time applications. Exit Games has been a client of…
The international law firm Taylor Wessing, led by Frankfurt based M&A partner Stephan Doom and Phil Shepherd from London, provided comprehensive legal advice to the International Chemical Investors Group (ICIG) on the acquisition of the sulphuric acid production plant in Bilbao from INEOS Enterprises. INEOS Sulphur Chemicals Spain SLU is Spain's largest dedicated manufacturer of sulphuric acid and oleum with applications ranging from the agricultural sector to chemical intermediates. The plant located in the harbour of Bilbao becomes part of the WeylChem Group, the fine chemicals…
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent (U.S. Patent No. 11,033,569) protecting the composition of matter of F-star’s SB 11285, a second generation STING agonist. The patent protection is expected to continue to July 2037, not…